---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-005538"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:18:05.875490+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences Q2 net loss $1.1M; expands DNase platform with VolitionRx SOW

## Summary
- Net loss of ~$1.1M for Q2 2023; R&D expenses fell 56.5% to ~$0.9M vs $2.1M in Q2 2022.
- Royalty payments from Takeda sublicense were ~$0.7M in Q2 2023, up 56.2% from prior year.
- Cash position of ~$10.7M at quarter end; no outstanding debt.
- Executed first Collaborator SOW with VolitionRx and CLS for NETs-targeted CAR T cell therapies in solid cancers.
- Advancing DNase-based oncology program towards Phase 1 study for pancreatic carcinoma and other solid tumors.

## SEC filing metadata
- accession: 0001683168-23-005538
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316823005538/0001683168-23-005538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316823005538/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-005538
- JSON: https://secwatch.observer/filing/0001683168-23-005538.json
- Plain text: https://secwatch.observer/filing/0001683168-23-005538.txt

## Key facts
- Earnings Releases
  Xenetic Biosciences, Inc. reported financial results for second quarter of 2023.
  - Period: second quarter of 2023
  - Result: reported results
  source text: On August 11, 2023, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the three months ended June 30, 2023 and providing a corporate update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and hereby incorporated in this Item 2.02 by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534525/000168316823005538/0001683168-23-005538-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.